CoGenesys has licensed rights to albumin fusion proteins that improve the bioavailability of proteins better than other methods such as PEGylation, its founders believe. The start-up's pipeline presently contains a version of BNP for treating heart failure.
9410 Key West Avenue
Rockville, MD 20850
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.
Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.
